Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
· 2019
ClinicalTrials.gov · Datasets · License: Public Domain · 2019
Open Source ↗
na
nsclc
nsclc, interventional, na
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)
#1048145
Magic Camp for Children With Hemiplegic Cerebral Palsy
#1048147
Impact of Different Restorative Treatments for Deep Caries Lesion in Primary Teeth
#1048148
Continuous Lumbar Plexus Block for Postoperative Pain Control After Total Hip Arthroplasty
#1048152
Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours
#1048144
Record
· ID 800187
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.